Subscribe To
Wework bankruptcy would deal another blow to ailing n.y. office market
The fallout would be particularly hard for landlords already struggling with piling debt and companies scaling back their office footprint....
November 4, 2023, 5:01 am
Convert new zealand dollar to afghan afghani
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review ma...
November 4, 2023, 4:59 am
Rwj: playing value in small caps means sacrificing quality
RWJ is a value-heavy smart-beta play offering exposure to a recalibrated version of the S&P 600. While having much stronger value characteristics than...
November 4, 2023, 3:52 am
Wip: not my favored inflation play
SPDR FTSE International Government Inflation-Protected Bond ETF has an underperformed other inflation protected products historically. WIP is a comple...
November 4, 2023, 2:10 am
What happens to bitcoin price if spot etf isn’t approved?
It’s not surprising that analysts expect to see negative short-term price action if a bitcoin spot ET...
November 4, 2023, 12:59 am
Canon isn't picture-perfect
Canon has operational advantages in its printing segment and has a strong global presence in various markets. However, the company's financial metrics...
November 4, 2023, 12:12 am
Seacor marine: good company, but not good enough
The OSV market is expected to face a deficit due to low order book levels and declining shipyard capacity, but growing demand from deep-water protects...
November 4, 2023, 12:05 am
Egain corporation (egan) q1 2024 earnings call transcript
eGain Corporation (NASDAQ:EGAN ) Q1 2024 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jim Byers - MKR IR Ashu Roy - CEO E...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Gold price analysis: paddling just beneath $2,000
Spot Gold has been trading on the top side of the 200-day SMA currently grinding towards $1,940, and Friday’s knock back from the $2,000 major handl...
November 3, 2023, 10:44 pm
Correction – the herzfeld caribbean basin fund, inc. announces estimated subscription price for rights offering
MIAMI BEACH, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by The Herzfeld Caribbean Basin Fund (...
November 3, 2023, 10:15 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Bdc weekly review: are bond swappers insulated from interest rate rises?
We take a look at the action in business development companies through the fourth week of October and highlight some of the key themes we are watching...
November 3, 2023, 8:19 pm
I wanna own apple, not trade it, says jim cramer
'Mad Money' host Jim Cramer gets to the core of Apple after a mixed earnings report....
November 3, 2023, 8:11 pm
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potential...
November 3, 2023, 8:05 pm
Prime medicine reports third quarter 2023 financial results and provides business updates
— Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well...
November 3, 2023, 8:01 pm